Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

R 192

Next Previous
Drug Profile

R 192

Alternative Names: R-192

Latest Information Update: 28 Mar 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Douglas Pharmaceuticals
  • Class Antidepressants; Anxiolytics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Anxiety disorders; Depressive disorders

Most Recent Events

  • 28 Mar 2022 Investigation in Anxiety disorders (PO)
  • 28 Mar 2022 Investigation in Depressive disorders (PO)
  • 21 Mar 2022 Zenith Technology Corporation plans a phase I clinical trial for Anxiety disorders and Depressive disorders (In volunteers) in New Zealand in May 2022 (PO, Tablet) (ACTRN12622000446763)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top